Below is a list of all AbbVie clinical trials in Canada that you or someone you know might be interested in joining. Find what you’re looking for by using the filters to narrow down the results. You can also see the full list of conditions in which AbbVie deals here.
The objective of this study is to evaluate real-world effectiveness of an active drug in Canadian women with endometriosis.
A study to assess the real-life management and use of healthcare resources during the initiation of:
The purpose of this study is to assess the safety and efficacy of an active drug for the treatment of moderate to severe atopic dermatitis (AD) in adult and adolescent subjects.
This is a registry study to evaluate the long-term safety and effectiveness of an active drug in patients with moderately to severely active UC who are treated as recommended in the product label.
An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of an active drug alone and in combination with paclitaxel or docetaxel.
The purpose of this study is to assess the safety and tolerability of an Active Drug in subjects with Parkinson's disease (PD).
An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of an active drug monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of an act
The study will determine the recommended Phase 2 dose (RP2D) of an active drug administered as monotherapy and in combination with an active drug as well as to assess the safety, pharmacokinetics (PK), and preliminary efficacy of an active drug alone a
This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of an active drug.
This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of an active drug, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for an active drug when administered as mono